Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LRY015
MIFTS: 30

Laryngeal Benign Neoplasm

Categories: Cancer diseases, Oral diseases, Respiratory diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Laryngeal Benign Neoplasm

About this section

MalaCards integrated aliases for Laryngeal Benign Neoplasm:

Name: Laryngeal Benign Neoplasm 12 15
Neoplasm of Larynx 12
Laryngeal Tumor 12
Larynx Neoplasm 12

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Respiratory diseases Oral diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:2598
MeSH 45 D007822
NCIt 51 C3156
UMLS 74 C0023055
Sources

Summaries for Laryngeal Benign Neoplasm

About this section
MalaCards based summary : Laryngeal Benign Neoplasm, also known as neoplasm of larynx, is related to larynx leiomyoma and laryngeal neuroendocrine tumor. An important gene associated with Laryngeal Benign Neoplasm is SLC22A23 (Solute Carrier Family 22 Member 23), and among its related pathways/superpathways is Adhesion. The drugs Cidofovir and Antiviral Agents have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and kidney.

Sources

Related Diseases for Laryngeal Benign Neoplasm

About this section

Diseases related to Laryngeal Benign Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 16)
# Related Disease Score Top Affiliating Genes
1 larynx leiomyoma 11.2
2 laryngeal neuroendocrine tumor 11.2
3 larynx cancer 10.1
4 laryngeal cartilage cancer 10.1
5 supraglottis cancer 10.1
6 respiratory system benign neoplasm 9.8 RAF1 SLC22A23
7 hemangioma 9.7
8 asbestosis 9.7
9 sarcoma 9.7
10 neuroendocrine carcinoma 9.7
11 granular cell tumor 9.7
12 capillary hemangioma 9.7
13 angiomyolipoma 9.7
14 spindle cell sarcoma 9.7
15 actinomycosis 9.7
16 asbestos intoxication 9.7

Graphical network of the top 20 diseases related to Laryngeal Benign Neoplasm:



Diseases related to Laryngeal Benign Neoplasm
Sources

Symptoms & Phenotypes for Laryngeal Benign Neoplasm

About this section
Sources

Drugs & Therapeutics for Laryngeal Benign Neoplasm

About this section

Drugs for Laryngeal Benign Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 155)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cidofovir Approved Phase 4 113852-37-2 60613
2 Antiviral Agents Phase 4,Phase 2
3 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
4
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
5
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
6
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124
7
Hydroxyurea Approved Phase 3,Phase 2,Phase 1 127-07-1 3657
8
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
9
Cetuximab Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 205923-56-4 56842117 2333
10
Cefazolin Approved Phase 3 25953-19-9 33255 656510
11
Ethanol Approved Phase 3 64-17-5 702
12
Nicotinamide Approved, Investigational Phase 3 98-92-0 936
13
Durvalumab Approved, Investigational Phase 2, Phase 3 1428935-60-7
14
Niacin Approved, Investigational, Nutraceutical Phase 3 59-67-6 938
15
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
16 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable
17 Antimetabolites Phase 3,Phase 2,Phase 1
18 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
19 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
20 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
21 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1
22 Antibodies, Monoclonal Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
23 Immunoglobulins Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
24 Antibodies Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
25 Antineoplastic Agents, Immunological Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
26 Anti-Bacterial Agents Phase 3,Phase 1
27 Nicotinic Acids Phase 3
28 Trace Elements Phase 3,Phase 2
29 Vitamin B9 Phase 3
30 Micronutrients Phase 3,Phase 2
31 Vitamin B3 Phase 3
32 Vasodilator Agents Phase 3
33 Vitamins Phase 3
34 Lipid Regulating Agents Phase 3
35 Nutrients Phase 3,Phase 2
36 Vitamin B Complex Phase 3
37 Hypolipidemic Agents Phase 3
38 Folate Phase 3
39 Immunoglobulin G Phase 2, Phase 3
40
Paclitaxel Approved, Vet_approved Phase 2,Phase 1,Not Applicable 33069-62-4 36314
41
Celecoxib Approved, Investigational Phase 1, Phase 2 169590-42-5 2662
42
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
43
Acetylcysteine Approved, Investigational Phase 2 616-91-1 12035
44 Raspberry Approved Phase 1, Phase 2
45
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
46
Sorafenib Approved, Investigational Phase 2,Phase 1 284461-73-0 216239 406563
47
Bortezomib Approved, Investigational Phase 2,Phase 1 179324-69-7 387447 93860
48
Irinotecan Approved, Investigational Phase 2,Phase 1 100286-90-6, 97682-44-5 60838
49
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
50
Sunitinib Approved, Investigational Phase 2,Phase 1 557795-19-4, 341031-54-7 5329102

Interventional clinical trials:

(show top 50) (show all 157)
# Name Status NCT ID Phase Drugs
1 Use of Cidofovir for Recurrent Respiratory Papillomatosis Completed NCT00205374 Phase 4 Cidofovir;Placebo
2 the Comparison of Voice Quality in Early Laryngeal Cancer Between Surgery and Radiotherapy Unknown status NCT00497588 Phase 3
3 Comparison of 2 Cefazolin Prophylactic Protocol in Laryngectomy Patients Completed NCT00467948 Phase 3 cefazolin
4 Randomized Trial to Assess the Impact of a Screening Program on Upper Aerodigestive Tract Cancer Mortality in a High Risk Population Completed NCT00359645 Phase 3
5 Induction CT by Cisplatin, 5FU With or Without Docetaxel in Patients With T3 and T4 Larynx and Hypopharynx Carcinoma Completed NCT00169182 Phase 3 DOCETAXEL;Cisplatin;5-Fluoro-3-Pyridinecarboxylic Acid
6 Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE) Completed NCT00117572 Phase 3 docetaxel;cisplatin;hydroxyurea;fluorouracil
7 Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCC Completed NCT00162708 Phase 2, Phase 3 CDDP, 5 Fu
8 Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC Completed NCT00158652 Phase 3 5FU, Paraplatin
9 Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin Recruiting NCT03258554 Phase 2, Phase 3
10 Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Active, not recruiting NCT01810913 Phase 2, Phase 3 cisplatin;docetaxel
11 Concurrent Chemoradiation Versus Surgery With Adjuvant Therapy in Advanced Laryngopharyngeal Cancers Terminated NCT00128817 Phase 3
12 Multicenter Phase II Study of Sentinel Node Detection in Squamous Cell Carcinoma T1-T2N0 of the Oropharynx Treated With Radiotherapy and Larynx Treated by Surgery, Laser or Robot Unknown status NCT03010553 Phase 2
13 Induction Docetaxel/Cisplatin/5-fluorouracil (TPF) as Selector for Chemo Radiation Therapy (RT) Versus Partial Laryngectomy in Advanced Laryngeal Cancer Unknown status NCT01073683 Phase 2 Taxotere (Docetaxel), Cisplatin, 5FU
14 PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Unknown status NCT01816984 Phase 1, Phase 2 PI3K inhibitor BKM120
15 Investigating the Impact of Tailored Reports on Anxiety Amongst Cancer Patients and Their Confidants Completed NCT00127465 Phase 1, Phase 2
16 Clinical Feasibility of New Tracheoesophageal Puncture Set Completed NCT01045057 Phase 1, Phase 2
17 Efficacy of Hyperbaric Oxygen Therapy in Laryngectomy Patients Completed NCT00026975 Phase 2
18 TPF Plus Radiotherapy and Cetuximab to Avoid Total Laryngectomy in Patients With Larynx Cancer Completed NCT00765011 Phase 2 TPF, radiotherapy and cetuximab
19 Endoscopic Surgery or Radiation Therapy in Treating Patients With Stage 0, Stage I, or Stage II Laryngeal Cancer of the Glottis Completed NCT00334997 Phase 2
20 Resistance Training During Radiation Therapy for Pharyngeal or Laryngeal Cancer Completed NCT00827164 Phase 2
21 Radiotherapy With Cisplatin Versus Radiotherapy With Cetuximab After Induction Chemotherapy for Larynx Preservation Completed NCT00169247 Phase 2 cetuximab;Cisplatin
22 Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer Completed NCT00970502 Phase 1, Phase 2 erlotinib + celecoxib
23 A Phase II Study In Patients With Advanced Head And Neck Cancer Of Standard Chemoradiation And Add-On Cetuximab Completed NCT01435252 Phase 2 Cetuximab
24 Docetaxel, Cisplatin (TP) + Radiation +/- Cetuximab in Larynx Carcinoma (CA) Completed NCT00508664 Phase 2 Cetuximab;Docetaxel;Cisplatin (TP);5-Fluorouracil (TPF) (only until Feb 2009)
25 Sargramostim to Prevent Mucositis in Patients Receiving Radiation Therapy for Laryngeal Cancer Completed NCT00004256 Phase 2
26 Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer Completed NCT00462735 Phase 2 Cetuximab;Hydroxyurea;Fluorouracil
27 Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy Completed NCT02123511 Phase 2 acetylcysteine
28 Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Stage III-IV Oropharynx, Hypopharynx, or Larynx Cancer Completed NCT02048020 Phase 2 paclitaxel;carboplatin
29 Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. Completed NCT01469429 Phase 1, Phase 2 chemoprevention;chemoprevention
30 Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer Completed NCT01316757 Phase 2 paclitaxel;carboplatin;erlotinib hydrochloride
31 Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck Completed NCT01044433 Phase 2 lapatinib ditosylate;capecitabine
32 Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Head and Neck Cancer Completed NCT00410826 Phase 2 erlotinib hydrochloride;cisplatin
33 Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab Completed NCT00939627 Phase 2 sorafenib tosylate
34 Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Completed NCT00114283 Phase 2 lapatinib ditosylate
35 Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed NCT00103259 Phase 2 bortezomib;irinotecan hydrochloride
36 Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00513435 Phase 2 saracatinib
37 Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00507767 Phase 2 dasatinib
38 Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer Completed NCT00387335 Phase 2 sunitinib malate
39 Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00055913 Phase 1, Phase 2 erlotinib hydrochloride
40 Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer Completed NCT00055770 Phase 1, Phase 2 erlotinib hydrochloride;docetaxel
41 Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer Completed NCT00098631 Phase 2 lapatinib ditosylate
42 S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00096512 Phase 2 sorafenib tosylate
43 SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00095628 Phase 2 ispinesib
44 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2 bevacizumab;placebo
45 Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck Completed NCT00033618 Phase 2 ixabepilone
46 Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer Completed NCT00101348 Phase 1, Phase 2 erlotinib hydrochloride
47 Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck Completed NCT00063895 Phase 1, Phase 2 erlotinib hydrochloride
48 Irreversible Electroporation(IRE) For Unresectable Laryngeal Neoplasms Recruiting NCT02430675 Phase 1, Phase 2
49 Dose Escalation Versus Standard in Laryngopharyngeal Cancers Recruiting NCT02757222 Phase 1, Phase 2
50 Vocal-cord vs. Complete Laryngeal Radiotherapy for Early Glottic Cancer Recruiting NCT03759431 Phase 2

Search NIH Clinical Center for Laryngeal Benign Neoplasm

Sources

Genetic Tests for Laryngeal Benign Neoplasm

About this section
Sources

Anatomical Context for Laryngeal Benign Neoplasm

About this section

MalaCards organs/tissues related to Laryngeal Benign Neoplasm:

42
Lung, Brain, Kidney, Liver, Testes, Breast, Colon
Sources

Publications for Laryngeal Benign Neoplasm

About this section

Articles related to Laryngeal Benign Neoplasm:

# Title Authors Year
1
Neoplasm of Larynx. ( 19988475 )
1931
2
Case of ? Neoplasm of Larynx. ( 19981052 )
1920
3
Case of ? Neoplasm of Larynx. ( 20905449 )
1920
Sources

Variations for Laryngeal Benign Neoplasm

About this section
Sources

Expression for Laryngeal Benign Neoplasm

About this section
Search GEO for disease gene expression data for Laryngeal Benign Neoplasm.
Sources

Pathways for Laryngeal Benign Neoplasm

About this section

Pathways related to Laryngeal Benign Neoplasm according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Adhesion 4
10.71 ARHGEF6 BSG
Sources

GO Terms for Laryngeal Benign Neoplasm

About this section

Biological processes related to Laryngeal Benign Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of Rho protein signal transduction GO:0035023 8.62 ARHGEF6 RAF1
Sources

Sources for Laryngeal Benign Neoplasm

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....